The abstract is read at the publisher; the summary is JClub's.
ZNF251 deficiency in BRCA1-mutant breast cancer cells induces replication stress and a pseudo-senescence state that enables PARP inhibitor resistance, reversible by senomorphic or senolytic targeting.
- Why it matters: PARP inhibitors are standard for HR-deficient cancers, but resistance limits durable benefit; this work addresses a mechanism and therapeutic leverage point.
- What they did: Using genome-wide CRISPR screening, the study links ZNF251 haploinsufficiency to HR hyperactivation and PARPi resistance, then tests senomorphic (cytokine inhibitors) and senolytic (BCL-2/BCL-XL inhibitors) approaches ex vivo and in vivo.
- The result: Senomorphic or senolytic therapies overcome PARPi resistance in ZNF251-deficient models, and pseudo-senescence also appears in other HR-hyperactivation-driven resistant contexts, while DT2216 sensitizes two olaparib-resistant BRCA-mutant triple-negative organoid models to olaparib.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.